Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) has been assigned a consensus broker rating score of 1.00 (Strong Buy) from the four brokers that provide coverage for the stock, Zacks Investment Research reports. Four analysts have rated the stock with a strong buy rating.

Brokers have set a 12-month consensus target price of $26.75 for the company, according to Zacks. Zacks has also given Verona Pharma PLC American Depositary Share an industry rank of 104 out of 265 based on the ratings given to its competitors.

A number of research firms recently commented on VRNA. Zacks Investment Research raised shares of Verona Pharma PLC American Depositary Share from a “hold” rating to a “buy” rating and set a $14.00 price target on the stock in a report on Tuesday, July 25th. SunTrust Banks, Inc. began coverage on shares of Verona Pharma PLC American Depositary Share in a report on Monday, May 22nd. They issued a “buy” rating and a $26.00 price target on the stock. Stifel Nicolaus began coverage on shares of Verona Pharma PLC American Depositary Share in a report on Monday, May 22nd. They issued a “buy” rating and a $22.00 price target on the stock. Jefferies Group LLC reaffirmed a “buy” rating and issued a $26.00 price target on shares of Verona Pharma PLC American Depositary Share in a report on Monday, May 22nd. Finally, Wedbush began coverage on shares of Verona Pharma PLC American Depositary Share in a report on Monday, May 22nd. They issued an “outperform” rating and a $25.00 price target on the stock.

Several large investors have recently bought and sold shares of the stock. Tekla Capital Management LLC bought a new stake in shares of Verona Pharma PLC American Depositary Share in the 2nd quarter worth approximately $3,211,000. FIL Ltd bought a new stake in shares of Verona Pharma PLC American Depositary Share in the 2nd quarter worth approximately $873,000. Finally, Vivo Capital LLC bought a new stake in shares of Verona Pharma PLC American Depositary Share in the 2nd quarter worth approximately $8,208,000. 30.16% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION WARNING: This piece of content was first published by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another site, it was stolen and reposted in violation of US & international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/09/08/zacks-analysts-set-26-75-price-target-for-verona-pharma-plc-american-depositary-share-vrna.html.

Verona Pharma PLC American Depositary Share (VRNA) opened at 16.66 on Friday. The stock has a 50 day moving average price of $12.35 and a 200 day moving average price of $13.57. Verona Pharma PLC American Depositary Share has a 52-week low of $11.03 and a 52-week high of $17.50. The firm’s market cap is $184.33 million.

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) last posted its quarterly earnings results on Tuesday, August 8th. The company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by $0.09. Equities analysts predict that Verona Pharma PLC American Depositary Share will post ($2.23) earnings per share for the current fiscal year.

Verona Pharma PLC American Depositary Share Company Profile

Verona Pharma plc, a clinical stage biopharmaceutical company, researches, discovers, and develops therapeutic drugs to treat respiratory diseases primarily in the United Kingdom and North America. The company’s lead product is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which is in Phase IIa clinical trial that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease, cystic fibrosis, and asthma.

Get a free copy of the Zacks research report on Verona Pharma PLC American Depositary Share (VRNA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Verona Pharma PLC American Depositary Share Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verona Pharma PLC American Depositary Share and related companies with MarketBeat.com's FREE daily email newsletter.